Last reviewed · How we verify

NCT04135235

Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B

Status unknown Last updated 22 October 2019
What this trial tests

trial testing TAF in Chronic Hepatitis B Infection in 440 participants. Status unknown.

Timeline
1 August 2019
Primary endpoint
1 August 2021
1 August 2021

Quick facts

Lead sponsorBeijing Ditan Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment440
Start date1 August 2019
Primary completion1 August 2021
Estimated completion1 August 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Ditan Hospital

Who can join

Adults 18 to 35, female only, with Chronic Hepatitis B Infection or High Viral Load. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective study. The subject will select 440 cases of pregnant women with high hepatitis B virus load, and one group will take maternal and child blockade treatment with propofol fumarate. One group will take tenofovir disoproxil fumarate. Broken treatment, compare the failure rate of maternal and child blockade and the incidence of maternal and child adverse events in the two groups, and explore the efficacy and safety of propofol flavuril for the treatment of hepatitis B mother-infant block.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of TAF

Trials testing the same drug.

Other recruiting trials for Chronic Hepatitis B Infection

Currently open trials in the same condition.

Other Beijing Ditan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04135235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing